Skip to content
drillr.ai
Sign up

RVTY

REVVITY, INC.

NYSE · Healthcare · Medical - Diagnostics & Research · US

$143.45
−2.24%
Ask drillr

  • Sep 9, 2026, 10:00 UTC

    Revvity, Inc. announced a definitive agreement to acquire France-based biotechnology company Human Cell Design, which specializes in human cell models for metabolic disease research, with the transaction expected to close in Q4 2026.

    Source:

  • Aug 20, 2026, 00:12 UTC

    On August 19, 2026, Revvity Inc's shares surged 5.0% to $119.45, within a 52-week range of $81.22 to $122.11.

    Source:

  • Aug 15, 2026, 07:27 UTC

    Assenagon Asset Management S.A. reduced its stake in Revvity Inc. by 35.5% during the quarter, selling 8,540 shares, leaving 15,483 shares, as disclosed in a 13F filing.

    Source:

  • Aug 13, 2026, 15:01 UTC

    Revvity launched SuperFlex, a compact automated prenatal screening system for smaller labs and clinics.

    Source:

  • Aug 10, 2026, 12:00 UTC

    Revvity, Inc. launched the SuperFlex prenatal screening system, a compact CE-IVDR certified immunoassay instrument for preeclampsia testing, on August 10, 2026.

    Source:

  • Aug 4, 2026, 10:00 UTC

    Revvity reported financial results for the second quarter ended July 5, 2026, with GAAP earnings per share of $0.48 and revenue of $730 million.

    Source:

  • Jul 31, 2026, 20:05 UTC

    Revvity, Inc. declared a regular quarterly dividend of $0.07 per share, payable on November 13, 2026 to shareholders of record on October 23, 2026.

    Source:

  • Jul 24, 2026, 16:05 UTC

    Revvity is developing a high-throughput T-SPOT.TB platform (T-SPOT A201) for clinical labs, targeting a 2027 launch.

    Source:

  • Jul 22, 2026, 16:05 UTC

    Revvity launched Signals for Startups, a software and onboarding service for early-stage biotech companies.

    Source:

  • Jul 20, 2026, 12:00 UTC

    Revvity launched the Signals for Startups program to help emerging biotech companies adopt scalable informatics capabilities.

    Source:

  • Jul 2, 2026, 15:01 UTC

    Revvity expands its Signals AI platform by integrating Anthropic's Claude through the Model Context Protocol ecosystem, providing scientists with secure access to connected R&D data and scientific context.

    Source:

  • Jun 22, 2026, 12:00 UTC

    Revvity launched Signals AI, a native agentic framework for accelerating scientific R&D, built into the Signals One platform.

    Source: